Motley Fool Money - 3 Stocks We Love in 2026

Episode Date: December 31, 2025

Are you looking for investment opportunities in 2026? So are we and we covered three stocks we love going into the year.Travis Hoium, Lou Whiteman, and Rachel Warren discuss: - Why space is worth watching in 2026- Opportunities in healthcare- How Hims & Hers is disrupting the healthcare industryCompanies discussed: Rocket Lab (RKLB), TransMedics (TMDX), Hims & Hers (HIMS). Host: Travis HoiumGuests: Lou Whiteman, Rachel WarrenEngineer: Bart Shannon Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, “TMF”) do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement. Learn more about your ad choices. Visit megaphone.fm/adchoices

The calendar is turning to 2026 tonight, so it's time to talk about stocks we love for 2026. Motley Full Money starts now. Welcome to Motleyful Money. I'm Travis Hoy. I'm joined by Lou Whiteman and Rachel Warren. We're going to do something a little bit different today, given it's a slow news week. We're going to talk about stocks that we like going into 2026.

It's always one of the times we focus on what is next year going to look like. So, Lou, let's get specific. What stocks do you like in 2020? All right. So I'm going to start with the sector, and then we'll get the stocks. I am really intrigued by space and what will become of the space sector in 2026. This was a real winner in 2025, all right? Lots of excitement. The arc space and defense innovation, ETF, which is kind of one way to look at it, up 50% for the year. That's not a bad year. A lot of these stocks we're talking about were did a lot better than that. That's how average is work. So in one sense, how can this continue, right? Once you had a year like this, there's no. way you can see that again, or that's like conventional wisdom. But on the other hand, it turns out SpaceX is going to IPO in 2026. $1.5 trillion is the rumored price, by the way. Yeah, we'll get to that in a second.

But yeah, even if they come in at half of that, there's going to be a lot of discussion, a lot of talk about the potential of space. And if that $1.5 trillion valuation does happen, hey, that makes a lot of these today's speculative stocks. Look, the valuation look really reasonable, right? So I think actually there can be momentum into 2026. Specific stocks, Rocket Lab is the leader. RKLB is to ticker.

I really like them. I'd rather own Rocket Lab than SpaceX, even if SpaceX was public. That's how I feel about Rocket Lab. But let's have more fun, something more obscure or something with a little more risk. I'm intrigued by Red Wire, ticker RDW. This is a component manufacturer for space and drones. They make a lot of the stuff that is necessary to get things into space. They have big exposure to,

areas like solar panels for space. There's stuff that you just need if you are going to put something into space. Very neat company. Motleyfoam members can just check out an interview I did with the CEO, Peter Cantillo. He described it as owning the fundamental building blocks, if we're going to have a golden agent space. They did a big acquisition in 2025. It's diversified to business.

I think it'll move them towards profitability in 2026. Lots of risks, lots of uncertainty. But it trades at 1.30th of the multiple Rocket Lab does right now. Price to sales multiple? Price to sales, because none of them are profitable yet. But yeah, the market hasn't discovered this one. No slam dunk. It could go to zero, but I am very intrigued by the opportunity.

One of the questions that I had when I saw this in the rundown is this is an area where these companies are not profitable. Usually I go to Lou for very sound. These companies are industrials. This is how they make money. This is how it's going to be durable for the next 20, 30, 40 years. This is much more speculative. What's the risk reward here?

because it seems like this could be an area where we go through a 2021 or 2022 style drawdown where suddenly that space ETF is down 70% in 2026. So it could be up another 50%, could be down 70%. Is that a fair way to look at the risk reward? I think it is. I mean, you're just setting it up, so I have to take it. It's a moonshot, baby, right? But no, here's what I'll say.

There are a lot of space startups right now. Most of them, and I've been following this area for a long time, Most of them, to me, are uninvestable right now because of the risk. What I like about RedWine, and look, again, there's no guarantees here, but the Edge Autonomy deal that they did, this big deal they did last year to move them into drones, that will also help cash flow. I think that they have joined Rocket Lab as companies that have enough they're there to survive a winter.

And, you know, look, there's no guarantees if it's a bad winter. We went from crypto winters, just potential space winters. Well, winter happens all over, Travis, right? So, no, I mean, I do think when you're looking at this, as optimistic as I am heading into 2026, you do have to realize that none of these things are slam dunks. They all could go to zero. So I do try to look at which ones I think can kind of outrun the Grim Reaper in a bad market. And I'm not sure on Red Wire.

It's hard to be sure of any equity. But I do like where they're set up, even if things are. don't go as well as I hope they will. This does seem like one of those areas, even if you're not investing in this space to start 2026, definitely worth having it on your watch list. Lou, I want to get an idea of what are we going to be thinking about with space five or ten years from now?

It seems like a lot of these companies are related in some way to communications. So you have SpaceX with Starlink, AST, Space Mobile, is a company that's putting up its own direct-to-sell network. They're going to be tying into other companies' networks. But is that sort of the early? early use case and what are we going to be looking at back going, okay, this was kind of the killer app for space because, you know, saying, hey, we're going to launch a bunch of satellites is cool. But if those satellites aren't adding value, then it isn't a sustainable business model.

Yeah, there's a lot of options here, right? I mean, the problem with communications is latency. For terrestrial communications, it can be second best. So it's just, it's an economics thing or a neat thing. I'll give you two candidates. I don't know if I would put my money on either one of them, but I think they're both out there. The whole, quote-unquote, data centers in space, you do have the latency problem there, too, but you have kind of the solar power side of it. You know, there is a lot of opportunity there. Jeff Bezos has talked about that. That's probably more than five years off, but that is intriguing. The other thing, Redwire has a small unit called Space MD. And what that is is pharmaceutical companies doing just experiments in space,

seeing how low gravity, zero gravity, just seeing how things work. I think there is some potential there, or at least some interest for revenue. I think once we're up there and established, then you start looking around. And I think it's going to be some boring, mundane thing that we're not thinking about now that's probably less glamorous than anything I said, but just makes life better in some way. You know, Lou, this is a really fascinating space. In particular, Rocket Lab. I know that they've had a lot of delays with the launches of their neutron rocket. They're looking to ahead and launch that by, between Q1 and Q2, I think, of next year. I think there's a lot of excitement in this space. What should we as investors kind of look for in terms of the key

hallmarks for these companies when evaluating space? It obviously is kind of a nascent industry in terms of investability. But what should we be looking for when we're looking at these companies? Rocket Lab specifically, you nailed it. The Neutron has to get off. And Peter Beck, the CEO, told Tom Gardner, look, we want to get it right the first time. He didn't name some. SpaceX, but SpaceX has no problem just launching things that explode until they don't. Rocket Lab has a very good record, and they claim the delays is just making sure they get it right the first time. That's great if it happens, but it will happen. More broadly, the way

I think investors should think about this is there are two hurdles, and we get focused on the first, and we kind of lose track of the second. For one, all of these things are basically glorified science projects, right? Like, we're just seeing if something works. We're trying technology, it has tried before. And the first hurdle is to find out if it works. And we tend to over invest in that. If it's possible, we say, okay, good, and we rush in. This is the hype cycle. The hype cycle. The second hurdle is, can I turn it into a long-term profitable business? Just because it's a science project, can it be long-term profitable? That is the hurdle, I think, is going to trip up a lot of these space-based businesses, I fear. And that's something that I am trying to filter out as I look at

these. Definitely a space to watch in 2026. When we come back, we're going to move to the medical industry. You're listening to Motley Fool Money. If you're early in your career and looking for insight, inspiration, and honest advice, listen to the Capital Ideas podcast, hear from Capital Group professionals about leaning into the differences that make you unique, making decisions that last, and what it means to lead with purpose. The Capital Ideas podcast from Capital Group, available wherever you listen, published by Capital Client Group, Inc. Welcome back to Motley Fool of Money. Rachel, you are up with your favorite stock going into 2026.

What are you looking at? Well, you know, I had to pick something in the healthcare space. I think this is a very fascinating industry. I think it receives sort of varying attention from investors, depending on the cycle that year and what investors are really looking at. One company I find really intriguing, it's a medical device company called Transmedics Group. So this is a commercial stage med tech company, and they've essentially pired. a new standard of care for organ transplantation.

So really the kind of core of the business is their organ care system or their OCS, as they call it. It is the only FDA-approved, portable, multi-organ platform for hearts, lungs, and livers. And it really has changed the standard for how these organs are moved for transplantation. So you've sort of got those traditional older methods, you know, static cold storage or placing organs on ice, if you will. But what the OCS does, what transmetics product does, is completely different. It essentially perfuses organs with warm, oxygenated blood, hearts can continue to beat, lungs continue to breathe, livers produce bile. Basically, what this means is that surgeons can better assess organ viability and optimize quality

before transplantation. And the technology really extends the time and distance that organs can travel. One of the things that's really unique about this business is not just the fact that They have a sort of first-to-market advantage, particularly in the U.S. But they've transitioned from being sort of a pure play medical device seller to a fully integrated logistics and service provider. And this is largely because back in 2023, they acquired a company called Summit Aviation. So they now operate their own fleet of aircraft.

It's about 21 planes at last count that I saw. And so they're basically able to control the entire transportation. chain when using their OCS system, they just expanded internationally in Italy through a partnership with Mercedes-Benz. Their primary clients are transplant centers and hospitals across the U.S. and now in their first key international target market, Italy, which is really, I think, the first part of their vision to expand more broadly internationally. And there's a lot of catalyst for future growth here. Obviously, there's the sort of revolutionary aspect of their technology. You know, this is a profitable business. This is a high-revenue growth business. And they tend to generate very high

margin recurring revenue, not just from the transplant fees, but also from these single-use plastic capsules and profusion sets that are needed for every transplant. It's a really interesting business. Not one maybe as frequently talked about in the healthcare space. Really intriguing company to watch, I think, as we get into the new year. If you look at the stock chart for Transmedics, this has been a really, really volatile ride over the past five years. Shares are actually up 560%, but man, you would have been up 500%, you know, and then down another 60% from there. So is this one of those where keep it on your radar, if we go through one of those

huge drawdowns? Because it seems like the catalyst for both the higher movements and the lower movements are crazy from quarter to quarter. That's when you may want to start nibbling or just, you know, set it and forget it. Don't worry about valuation in 20 years. This is going to be a revolutionary company. How do you think about that, Rachel? Yeah, I personally think it's one worth nibbling on.

And I think it's interesting to know, to me, but you look at the healthcare space. You have sort of a smaller subset of these growth-oriented businesses that tend to see these very wild-priced reactions. And again, as I noted, you know, Transmedics is profitable. They have a pretty favorable balance sheet overall. You know, they're not one of these early stage, unprofitable biotechs. Sort of in other lane in the healthcare space, you have a lot of those slower-growing pharmaceutical companies that don't necessarily bring forth those wild price reactions, but don't necessarily, you know, bring forward that growth either. And I think this is an interesting

example of a growth play in the healthcare space. You know, I will note, they are sort of the market leader within the U.S. I mean, their portable systems hold more than half the market share. And a lot of this is because of their necessity in long-distance decentralized transplant networks, that vertically integrated business model has been really key. I would certainly expect more volatility ahead. You know, they're not the only player in this space, but they are the market leader. And there are a couple other things as well, you know, to note. They're right now focused on initiating two major clinical trials, which are expected to really be the main catalyst for their future growth, additional approvals for their organ care system. That's something that's really

important to watch for. You know, the broader, the use cases and applications for their system, the more they extend that one way of growth for the business. One of the trials is expected to basically drive further adoption in the lung transplant market where they are a key player. But the other is the largest heart preservation for transplant trial ever. It's expected to enroll over 650 patients. So that's another key area to watch with this business. I'm glad you mentioned that to trials, because I've looked at this a bunch of times. And the thing that gets me is, for one, the core market, it's just not growing the way. And part of that is just availability and just going to, there's only so many transplants out there with the transportation business, that is hard to scale without cost. You know,

you just can't do that without cost, so you need that. You couple it with, there was a short report. I thought it was mostly, you know, not great, but the one thing that I think was Scorpion Capital said, there does seem to be some interest from the government to kind of overhaul the whole transplant market, including Medicare reimbursement, considering how expensive TransMedic is, I think that's at least something to watch. A lot of it is just because this is a costly thing, and it's life-saving. So, you know, I can't find red flags. But the trials better work out. They better figure out how to scale and add more just kind of the infrastructure at cost. And then with the government hanging over, Europe seems intriguing, but just the way payments work over there for

healthcare versus Medicare. I don't know. I think this needs to be a U.S. story. And I think it's almost back to what we said about space. I love the science project. I love what they're able to do. But turning it into a scalable, growing business is not an insurmountable problem, but it is going to be a bear.

Well, definitely an interesting one to watch going into 2026. When we come back, I'm actually going to play. I'm going to bring a stock to the table that I think will get some thoughts from Lou and Rachel. You're listening to Motley Fool Money. These days I'm all about quality over quantity, especially in my closet. If it's not well-made and versatile, it's just not worth it. That's honestly what I love Quince. The fabrics feel elevated, the cuts are thoughtful, and the pricing actually makes sense.

Quince makes high-quality wardrobe staples using premium fabrics like 100% European linen, silk, and organic cotton poplin. They work directly with safe ethical factories and cut off the middlemen, so you aren't paying for brand markups or fancy stores, just quality clothing. Everything they make is built to hold up season after. season and is consistently rated 4.5 to 5 stars by thousands of real people like me who wear their clothes every day. The Quince, Mongolian Kashmir Kru Neck sweater may be the most comfortable one that I own. It's light, soft, and it was a lot more affordable than you think quality cashmere would be. Stop waiting to build the wardrobe you actually want. Right now, go to quince.com slash Motley for free shipping and 365-day returns. That's a full year to wear it and love it,

and you will. Now available in Canada, too. Don't keep settling for clothes. that don't last. Go to Q-I-N-C-E.com slash Motley for free shipping and 365-day returns. Quince.com slash Motley. Welcome back to Motley Fool Money. As the host, today, I decided to bring a stock to the table as well. If you got our Spotify wrapped, if you're listening to this on Spotify, you may be familiar with this stock.

I did a little AI video where I recorded myself doing my stock pick and then riding a rocket into space. So a little bit up-lose alley there. But I wanted to bring Hymns and Mawks and. hers to the table. This is a healthcare company, but it's a little bit more like a wrecking ball than a traditional pharmaceutical or insurance company. They live outside of insurance. They have compounding facilities, which are legal but controversial. The first place to really scale some of these aspects of weight loss, they started with ED, you have hair loss, hair treatments. They're

moving into testosterone, perimenopause, longevity is coming. But this is one of the real disruptors in the space, and I think they're thinking about healthcare very differently. It looks a lot more to me like Netflix or Amazon, where they're pulling all of the demand together. And this is one of the things that we've learned throughout the history of technologies. The companies that can pull demand together can then kind of bring supply to the table on their terms. This is exactly why you have companies like Paramount and Warner Brothers Discovery in a little bit

of trouble because people don't go to their apps. they go to Netflix. So that's where the power is in the market is aggregating that demand. And they're bringing interesting solutions. They have this artificial intelligence play. I don't like investing in companies that are just, hey, they're going to use AI. But there is a case to be made that in the medical field, a single human can only understand or remember so many things.

And given the complex system that is the human body, and AI could potentially absorb much more data, especially on a real-time basis. I mean, I always think about, I'm wearing a Garmin watch. If I take this data from my Garmin watch to my doctor, they're going to go, what in the world am I supposed to do with that? But that's the kind of thing that can plug into a platform like Hims and Hers. That said, I know that this is not the favorite. This is actually a huge short interest.

The short interest is over 30%. So that can be either good or bad, depending on how you look at it. There could be a short squeeze, but the shorts could also be right. Rachel, I know this is one that you follow. what are your thoughts, either positive or negative, on Hymns & HERS going into 2026? Yeah, I'm glad you brought this one up. And I also glad you mentioned that short interest. It's kind of fascinating.

I think a lot of the attention and also some of the sort of negative investor attention as well that Hems and HERS has received this year has been down to that GLP1 business. But I want to say I really like Hems and HERS as a platform. I think that the model is sticky well beyond any success they do or don't continue to have within the GLP1 space. And I want to emphasize that because there, I think, have been some very kind of justifiable concerns about how they have approached that. I mean, we've talked in the past about that agreement they had with Nova Nordisk and the Nova Nordisk backed out. It's worth noting that Nova is still working with other telehealth companies like Roe, for example, because Roe adhered to their terms to only offer the, you know, authentic branded branded Wigovie. Well, and you can still buy, I believe, their products through Hymns and hers, but it's not at a discounted price. I think it's still pretty expensive.

Part of it was they wanted to... The discounted offering. Yeah, it was a discounted offer. And then it would be just funneling to Novo Nordisk's online system. I wonder what the real battle was there because Novo did sue, or Eli Lilly, one of those companies sued a whole bunch of compounders, did not sue him's and hers. I think that is an interesting piece of that picture because that was always the risk, was this huge legal risk.

And that never materialized in 2025. Well, and of course, there had also been some interactions between, you know, Eli Lilly and him's and hers, and that sort of pre-established relationship can also kind of create some legal hurdles when it comes to, you know, pursuing legal action. I think there has been some confusion about why there was this issue here. You know, bear in mind, under legal exemptions, you know, compounders, they can still produce a drug if it's significantly different from the branded version. Now, the semi-glutide shortage ended almost a year ago, but there are these legal exemptions that allow compounders like Hymns and HERS to produce essentially individualized doses. So there might be minor

tweaks because there's a particular allergy to a certain element. But in practice, it can also mean that you're basically selling compounded medications that are made in outsourcing facilities that do follow federal manufacturing standards, but they don't have the specific drug formulation verified by the FDA. And so that's where some of that's concern has come from. Now, we heard back in November that Hymn and HERS is maybe talking with Novenortis again. Maybe they're, you know, you know, re-engaging. They're also selling a generic Lyr-glutide, which is basically an older GLP-1. It's not protected by patent, and so it could be legally compounded without a shortage. So we'll see where this goes. I think there's a lot of interest in this business because of

GLP-1. I understand that. But I think there are other tailwinds for the company that they're watching. Yeah, and to be clear, GLP-1s and weight loss is something like 20% of their business. It has been interesting to watch that, you know. It's moved to the stock. It's moved the stock a ton, but it is not really the driver of the business and now you move into things like labs. I mean, just to test it, I got my labs done incredibly efficient. You go to a traditional labs facility, but I was getting results within 24 hours and just come straight to your phone. Lou, did you have thoughts on that? I tried to pick one that, you know, both of you would at least have an opinion on whether it was good or bad. All I'd say on this is is that this is a market that desperately needs disruption.

So I'm rooting for them. But it's also between regulation and, you know, it is life or death. You got to get it right. With Hymns and hers, I would just make sure the management team reads the story of Icarus because, you know, there is a real risk of flying too close to the sun here. And I think we have seen that and they've had growing pains as they've done that. I do think that there is a path towards success here, but there is a lot of risk if you're pushing the envelope with people's health. So I get both the skepticism and the excitement.

And again, I wish them well because our health system is. broken. It will definitely be another one to watch. So Rocket Lab, Transmedics, and Hymns and hers, if you were looking for some ideas going into 2026. As always, people on the program may have interest in the stocks they talk about, and the Motley Fool may have formal recommendations for or against, so don't buy our sell stocks based solely on what you hear. All personal finance content follows the Motley Fool's editorial standards. It is not approved by advertisers. Advertisements are sponsored content and provided for informational purposes only to see our full advertising disclosure. Please check out our show notes. For Lou

Whiteman, Rachel Warren, Fart Shane behind the glass. I'm Travis Flam. We'll be back after the New Year on Friday. We'll see you then.